2H-1,4-苯并噁嗪-3(4H)-酮,6-[(4,5-二氢-1H-咪唑-2-基)氨基]-5-甲基- | 179863-46-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 中文名称: 2H-1,4-苯并噁嗪-3(4H)-酮,6-[(4,5-二氢-1H-咪唑-2-基)氨基]-5-甲基-
• 英文名称: 6-(imidazolidin-2-ylidene amino)-5-methyl-4H-benzo[1,4]oxazin-3-one
• 英文别名: 6-(imidazolidin-2-ylideneamino)-5-methyl-4H-benzo[1,4]oxazin-3-one；6-(4,5-dihydro-1H-imidazol-2-ylamino)-5-methyl-4H-1,4-benzoxazin-3-one
• CAS: 179863-46-8
• 化学式: C₁₂H₁₄N₄O₂
• 分子量: 246.269
• InChiKey: GWKHUNDDZLCWRU-UHFFFAOYSA-N

物化性质

• 密度：
  1.51±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  74.8
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2H-1,4-苯并噁嗪-3(4H)-酮,6-[(4,5-二氢-1H-咪唑-2-基)氨基]-5-甲基- 在 dimethyl sulfide borane 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 生成 AGN 193080
  参考文献：
  名称：

  Synthesis and Evaluation of 2-[(5-Methylbenz-1-ox-4-azin-6-yl)imino]imidazoline, a Potent, Peripherally Acting α₂ Adrenoceptor Agonist

  摘要：

  We have synthesized 2-[(5-methylbenz-1-ox-4-azin-6-yl)imino] imidazoline, 3, a potent, peripherally acting alpha(2) adrenoceptor agonist. The agent is prepared in five steps from 2-amino-m-cresol. The agent has demonstrated good selectivity for alpha(2) adrenoceptors in binding and functional studies. When applied topically to eyes, the agent is efficacious for the reduction of intraocular pressure. The agent does not penetrate the blood-brain barrier and, as a consequence, does not lower blood pressure or induce sedation when administered topically or intravenously. We have determined the pK(a) and log P in water versus both octanol and dodecane of 3 and a set of related agents. The best physical parameter to explain its lack of central nervous system penetration appears to be log P measured in octanol versus water.

  DOI：

  10.1021/jm960359r
• 作为产物：
  描述：

  2-氨基-3-甲基苯酚 在 palladium on activated charcoal 4-二甲氨基吡啶 、 硫酸 、 氢气 、 硝酸 、 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 112.0h， 生成 2H-1,4-苯并噁嗪-3(4H)-酮,6-[(4,5-二氢-1H-咪唑-2-基)氨基]-5-甲基-
  参考文献：
  名称：

  Synthesis and Evaluation of 2-[(5-Methylbenz-1-ox-4-azin-6-yl)imino]imidazoline, a Potent, Peripherally Acting α₂ Adrenoceptor Agonist

  摘要：

  We have synthesized 2-[(5-methylbenz-1-ox-4-azin-6-yl)imino] imidazoline, 3, a potent, peripherally acting alpha(2) adrenoceptor agonist. The agent is prepared in five steps from 2-amino-m-cresol. The agent has demonstrated good selectivity for alpha(2) adrenoceptors in binding and functional studies. When applied topically to eyes, the agent is efficacious for the reduction of intraocular pressure. The agent does not penetrate the blood-brain barrier and, as a consequence, does not lower blood pressure or induce sedation when administered topically or intravenously. We have determined the pK(a) and log P in water versus both octanol and dodecane of 3 and a set of related agents. The best physical parameter to explain its lack of central nervous system penetration appears to be log P measured in octanol versus water.

  DOI：

  10.1021/jm960359r

文献信息

• Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B / 2C adrenergic receptors
  申请人：Allergan Sales, Inc.

  公开号：US20020156076A1

  公开（公告）日：2002-10-24

  Compounds having adrenergic activity which are a selective agonists for one or both of the &agr; 2B and &agr; 2c adrenoceptor receptor subtypes in preference to the &agr; 2A adrenoceptor receptor subtype; the active compound being selected from the group consisting of compounds having the formula 1 wherein the dotted lines represent optional bonds provided that two double bonds may not share a common carbon atom; R is H or lower alkyl; X is S or C(H)R 1 , wherein R 1 is H or lower alkyl, but R 1 is absent when the bond between X and the ring represented by 2 is a double bond; Y is O, N, S, (CR 1 2 ) y , wherein y is an integer of from 1 to 3, —CH═CH— or —Y 1 CH 2 —, wherein Y 1 is O, N or S; x is an integer of 1 or 2, wherein x is 1 when R 2 , R 3 or R 4 is bound to an unsaturated carbon atom and x is 2 when R 2 , R 3 or R 4 is bonded to a saturated carbon atom; R 2 is H, lower alkyl, halogen, hydroxy, lower alkoxy, lower alkenyl, acyl or lower alkynyl, or, when attached to a saturated carbon atom, R 2 may be oxo; R 3 and R 4 are, each, H, lower alkyl, halogen, lower alkenyl, acyl, lower alkynyl, aryl, heteroaryl, or sub stituted aryl or heteroaryl, wherein said substituent is halogen, lower alkyl, lower alkoxy, lower alkenyl, acyl, lower alkynyl, nitro, cyano, trifluoromethyl, hydroxy, or phenyl or, together, are —(C(R 2 )x)z—; —Y 1 (C(R 2 )x)z′—; —Y 1 (C(R 2 )x)y Y 1 —; —(C(R 2 )x)—Y 1 —(C(R 2 )x)—; —(C(R 2 )x)—Y 1 —(C(R 2 )x)—(C(R 2 )x)— and —Y 1 —(C(R 2 )x)—Y 1 —(C(R 2 )x)— wherein z is an integer of from 3 to 5, z′ is an integer of from 2 to 4 and x and y are as defined above, and further either end of each of these divalent moieties may attach at either R3 or R4 to form a condensed ring structure and the rings formed may be totally unsaturated, partially unsaturated, or totally saturated; and being useful for treating muscle spasticity including hyperactive micturition, diarrhea, diuresis, withdrawal syndromes, pain including neuropathic pain, neurodegenerative diseases, memory and cognition deficits, psychoses including manic disorders and anxiety, hypertension, cardiac ischemia, congestive heart failure, and nasal congestion without sedating or cardiovascular side effects.

  具有肾上腺素活性的化合物，是选择性激动剂，优先作用于α2B和α2C肾上腺素受体亚型中的一个或两个，而不是α2A肾上腺素受体亚型；所述活性化合物从以下化合物组中选择，其具有下列式1的化合物，其中虚线代表可选键，但两个双键不能共用一个碳原子；R为H或较低的烷基；X为S或C(H)R1，其中R1为H或较低的烷基，但当X与由2表示的环之间的键为双键时，R1不存在；Y为O、N、S、(CR12)y，其中y为1至3的整数，—CH2CH—或—Y1CH2—，其中Y1为O、N或S；x为1或2的整数，当R2、R3或R4与不饱和碳原子结合时，x为1，当R2、R3或R4与饱和碳原子结合时，x为2；R2为H、较低的烷基、卤素、羟基、较低的烷氧基、较低的烯基、酰基或较低的炔基，或者当连接到饱和碳原子时，R2可能为酮基；R3和R4分别为H、较低的烷基、卤素、较低的烯基、酰基、较低的炔基、芳基、杂环芳基或取代的芳基或杂环芳基，其中所述取代基为卤素、较低的烷基、较低的烷氧基、较低的烯基、酰基、较低的炔基、硝基、氰基、三氟甲基、羟基或苯基，或者共同为—(C(R2)x)z—；—Y1(C(R2)x)z′—；—Y1(C(R2)x)y Y1—；—(C(R2)x)—Y1—(C(R2)x)—；—(C(R2)x)—Y1—(C(R2)x)—(C(R2)x)—和—Y1—(C(R2)x)—Y1—(C(R2)x)—其中z为3至5的整数，z′为2至4的整数，x和y如上所定义，而且这些二价基团的每一端都可以连接到R3或R4中的任一端，形成一个紧凑的环结构，所形成的环可以是完全不饱和的、部分不饱和的或完全饱和的；并且适用于治疗肌肉痉挛，包括过度活跃的小便、腹泻、利尿、戒断综合征、包括神经病理性疼痛、神经退行性疾病、记忆和认知缺陷、精神病，包括躁狂障碍和焦虑、高血压、心肌缺血、充血性心力衰竭和鼻塞，无镇静或心血管副作用。
• Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
  申请人：ALLERGAN SALES, INC.

  公开号：US20030023098A1

  公开（公告）日：2003-01-30

  Methods and compounds for the treatment of conditions including pain, particularly chronic pain, glaucoma or elevated intraocular pressure with reduced cardiovascular or sedative side effects. Also included are methods of making and using such compounds.

  用于治疗疼痛、特别是慢性疼痛、青光眼或高眼压的方法和化合物，具有减少心血管或镇静副作用。还包括制备和使用这些化合物的方法。
• Imidiazoles having reduced side effects
  申请人：Chow Ken

  公开号：US06841684B2

  公开（公告）日：2005-01-11

  Methods and compounds for the treatment of conditions including pain, particularly chronic pain, glaucoma or elevated intraocular pressure with reduced cardiovascular or sedative side effects. Also included are methods of making and using such compounds.

  本发明涉及用于治疗疼痛、尤其是慢性疼痛、青光眼或眼内压升高的方法和化合物，其具有降低心血管或镇静副作用的特点。还包括制备和使用这种化合物的方法。
• Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors
  申请人：Allergan, Inc.

  公开号：EP1413576A2

  公开（公告）日：2004-04-28

  Coumpounds having adrenergic activity which are selective agonists for one or both of the α2B and α2C adrenoceptor receptor subtypes in preference to the α2A adrenoceptor receptor subtype; the active compound being selected from the group consisting of compounds having formula (I) wherein the dotted lines represent optional bonds provided that two double bonds may not share a common carbon atom; R is H or lower alkyl; X is S or C(H)R1, wherein R1 is H or lower alkyl, but R1 is absent when the bond between X and the ring represented by formula (a) is a double bond; Y is O, N, S, (CR12)y, wherein y is an integer of from 1 to 3, -CH=CH- or -Y1CH2-, wherein Y1 is O, N or S; x is an integer of 1 or 2, wherein x is 1 when R2, R3 or R4 is bound to a saturated carbon atom and x is 2 when R2, R3 or R4 is bound to a saturated carbon atom; R2 is H, lower alkyl, halogen, hydroxy or lower alkoxy, or, when attached to a saturated carbon atom, R2 may be oxo; R3 and R4 are, each, H, lower alkyl, hydroxy, lower alkoxy, or phenyl or, together, are -(C(R2)x)z-; -Y1(C(R2)x)z'-; -Y1(C(R2)x)yY1-; -(C(R2)x)-Y1-(C(R2)x)-; -(C(R2)x)-Y1-(C(R2)x)-(C(R2)x)- and -Y1-(C(R2)x)-Y1-(C(R2)x)- wherein z is an integer of from 3 to 5, z' is an integer of from 2 to 4 and x and y are as defined above, and further either end of each of these divalent moieties may attach at either R3 or R4 to form a condensed ring structure and the rings formed may be totally unsaturated, partially unsaturated, or totally saturated; and being useful for treating muscle spasticity including hyperactive micturition, diarrhea, diuresis, withdrawal syndromes, pain including neuropathic pain, neurodegenerative diseases, memory and cognition deficits, psychoses including manic disorders and anxiety, hypertension, cardiac ischemia, congestive heart failure, and nasal congestion without sedating or cardiovascular side effects.

  具有肾上腺素能活性的偶联化合物，是一种或两种 α2B和α2C肾上腺素受体亚型的选择性激动剂，优于α2A肾上腺素受体亚型；活性化合物选自由式(I)组成的化合物组，其中虚线代表任选键，但两个双键不得共用一个碳原子；R是H或低级烷基；X 是 S 或 C(H)R1，其中 R1 是 H 或低级烷基，但当 X 与式 (a) 所代表的环之间的键是双键时，R1 不存在； Y 是 O、N、S、(CR12)y（其中 y 是 1 至 3 的整数）、-CH=CH- 或 -Y1CH2-，其中 Y1 是 O、N 或 S；x 是 1 或 2 的整数，其中，当 R2、R3 或 R4 与饱和碳原子结合时，x 为 1，当 R2、R3 或 R4 与饱和碳原子结合时，x 为 2；R2 是 H、低级烷基、卤素、羟基或低级烷氧基，或者，当与饱和碳原子连接时，R2 可以是氧代；R3 和 R4 分别是 H、低级烷基、羟基、低级烷氧基或苯基，或者合在一起是-(C(R2)x)z-；-Y1(C(R2)x)z'-；-Y1(C(R2)x)yY1-；-(C(R2)x)-Y1-(C(R2)x)-；-(C(R2)x)-Y1-(C(R2)x)-(C(R2)x)-和-Y1-(C(R2)x)-Y1-(C(R2)x)- 其中 z 是 3 至 5 的整数，z'是 2 至 4 的整数，x 和 y 如上文所定义、此外，这些二价分子的任何一端都可以连接到 R3 或 R4 上，形成缩合环结构，所形成的环可以是完全不饱和、部分不饱和或完全饱和的；可用于治疗肌肉痉挛（包括排尿亢进）、腹泻、利尿、戒断综合征、疼痛（包括神经性疼痛）、神经退行性疾病、记忆和认知障碍、精神病（包括躁狂症和焦虑症）、高血压、心脏缺血、充血性心力衰竭和鼻塞，且无镇静或心血管副作用。
• [EN] COMPOSITIONS AND THEIR USES FOR ALLEVIATING PAIN<br/>[FR] NOUVEAUX PROCEDES ET NOUVELLES COMPOSITIONS DESTINEES A SOULAGER LA DOULEUR
  申请人：——

  公开号：WO2003099289A3

  公开（公告）日：2004-03-18